Get started

ZYNE

Perfect Double Bottom for ZYNEDouble bottom in an uptrend: - The double bottom looks like the letter "W". The twice-touched low is considered a support level. - The advance of the first bottom should be a drop of 10% to 20%, then the second bottom should form within 3% to 4% of the previous low, and volume on the ensuing advance should increase. - The double bottom pattern always follows a major or minor downtrend in a particular security, and signals the reversal and the beginning of a potential uptrend. Out of the most interesting cannabis bio pharma companies (GWPH, CARA and ZYNE), this one seems to be ready for another break out. I'm anticipating a quick retrace, then a break through resistance to test the next level. Just my 2 cents. It's free. Trade with caution.
Z
by Barkworth
ZYNE strong bull breakout or trading range?Although $ZYNE is developing some bull strength, it is still in a large bear trend or trading range. The bulls reversed the market up on the monthly chart from a large high 2, and will probably get some form of a second leg up. However since the IPO this market has been sideways to down, decreasing the likelihood of a strong bull trend developing. The bulls need strong follow through above the 25 lower high and a strong breakout above the all time high in order to convert into a bull trend. Instead, there will likely be resistance around the $23 bear gap, bulls will take profits and bears will try to form a lower high and bear trend continuation. If you found this helpful please like! Feel free to comment or ask questions.
Z
by tradersmentality
Buying a bull flag with ZYNEI got in at $3.66. Been in and out, trying to sell the rallies and buy the dip. It has been an interesting ride with some extreme gains. Needless to say that my position is bullish. So... what's next? My play with ZYNE is aimed at the CBD legislation that is expected at around October this year. ZYNE has many good patents, ready to market, and once CBD as an additive becomes 'legal', I think ZYNE is well set up to gain from that. I also particularly like that ZYNE is a USA based play. The most recent move up seems a bit too extended, and with the current price level, volume will probably leave for other plays, for now. I see a target area of former glory, between $16.50 and about $23. Gann tells me we'll be trading in a bit of a wedge, sideways, if nothing bad happens. That means we'll see a bull flag of sorts, right until it is time for ZYNE again to choose direction. As long as we hold the $12.90 level, and sustain an occasional dip, I think we should be ready to retest $16.48 in a few weeks. For a long play, imagine ZYNE getting one of their Phase 3 medicine approved for marketing. BOOOM!!! I mean, that is exactly what happened with GWPH. 300% gains, for starters. Without Epidiolex, they would still be $50. Could take some time, but other than CARA, there really is no similar play in this industry. Therefore I think that these current levels are still a fantastic entry point. But keep in mind that failing trials will send a stock down just as hard. #LongZYNE
Z
by Barkworth
Healthy consolidation for ZYNEIt would seem that ZYNE got a bit ahead of itself. We were very extended on 26, 29 and 30 April, and finally saw some healthy consolidation with an initial 5% pull back. SPY was making ripples yesterday, and probably added much to panic reaction, more than 20% down. I bought that dip with much gratitude, and relished when buying pressure forced her back up to $11.40. If we assume that the recent high of $13.06 marks the end of this cycle, we'll probably see some lower highs and lower lows/higher lows, leading the price back to the 45 degree line, most likely keeping the range roughly between $10 and $12 for now. On the other hand, if bulls break the $13 price resistance, we'll see another leg up. Perhaps that is why we always say "levels on watch". I expect the 45 degree trend line to be strong, as it has been 'touched' 3 times. Keep in mind that ZYNE is only just starting on its rebound journey upward. If you think you've missed it, I think you're wrong. I think the entry is now, with targets of $15 within weeks, and $25 and $36 within the next 6 to 8 months. What we're hoping to see from ZYNE, is a great Phase 3 trial results, and for the broader market, the legalisation of CBD as an additive, etc. so that Zynerba can start marketing its wide range of unique patents. When that bit is behind us, CBD legalisation in the European Union is next. Also for GWPH, btw. Safe trading, everybody!
Z
by Barkworth
ZYNE at key resistanceWe need to see ZYNE break $12.05 with confidence today. If she does, we'll see the 100EMA cross the 150EMA. In any event, I really don't think we're looking at any deeper pull back at the moment. ZYNE is happening. I have a bullish position right now, so I am just going to hold. If we break upward today, I'm going to add to my position. Roth just added a $36 target for ZYNE. This is a company that holds a set of CBD patents that each of them has excellent potential when CBD gets legalised in the US of A. #long ZYNE
Z
by Barkworth
ZYNE levels on watchThe Stoch RSI shows that we still may have some power for a move up, but volume has been on the decline, even if it is still well above average. In addition, we're looking pretty extended on the daily chart. I closed half my position in anticipation of a potential retrace, before a new leg up. I have studied ZYNE's historical movements, and its behaviour is quite predictable, once you figure out which way she wants to go. For Monday, if there will be another leg up, we're likely to see her bounce on $10.34. If the bulls are exhausted for now, we'll see a short term retrace to $9.90 and $9.40, and if the consolidation period lasts longer, we may see $8.75 again. We have seen that ZYNE doesn't need a lot of volume to move up. If we look at the start of the current uptrend, there is an extended daily candle on the second day, that saw a bullish follow up, the day after, with just half the volume. Looking at the half way retrace, she bounced on the 12EMA. That will be around $9.40, this time. I'll continue this with a longer term FIB retracement overview.
Z
by Barkworth
ZYNE hourly levels on watchWere we looking at residual buying pressure yesterday, or is ZYNE ready for another leg up? Analyst targets are all well above $10, and the projected upside is about 300%, but to assume that it will just skyrocket in that direction seem unreasonable. Bears took control in the second half of yesterday's session. The level to hold is $8.38. the levels to break are $9.15 and $9.48. ZYNE has done it before, and after consolidation of about $1 yesterday, it is not irrational to anticipate another bull run. There is the possibility of a Head & Shoulders pattern emerging. We'll have to see a lower low, followed by a retrace towards the $8.40 level. If she makes this move and fails to hold supports, we may be looking at a bearish trend reversal, in which case the FIB levels become of interest.
Z
by Barkworth
ZYNE takes a breathAt $8.17, ZYNE was up 47% this week. Volume saw more than 50% of its share count exchange hands - though we probably saw a few million shares traded several times - and yesterday we saw a healthy bounce. There is still some volume, we could be looking at residue buying power and we need to have the levels on watch to find short term direction. Today we need to see bulls break $8.17 if we want to look for a higher high. I think that the most likely scenario will see a quick squeeze up, followed by a sell off, bouncing again, leading us to the $7.50 levels to take us into the weekend.
Z
by Barkworth
ZYNE, when and how...Zynerba is one of my favourite biopharma stocks. I've played her from $3.88 up to $5.22, then sold when I saw that the hype was temporarily over. I didn't want to go long ZYNE, because biopharma is some scary stuff. When they presented failed trials earlier, the stock plunged 53%. On the other hand, when a trial succeeds, and a medicine can be filed and prepped for marketing, it is a potential almost without limits. ZYNE has a patent gel, which is important, because it is hard to get CBD into your body if you don't want to smoke or eat it. I was just looking at GW PHarma... Second one out, first one with epilepsy medicine... Zynerba is expected to break even this year. Current trial phases are published on their website. Short term, I don't see much of a bullish trend, just investors getting on board at specific publications. My plan is to wait for it to reach, what I see as, the buy zone. I'm planning to take a moderate position there.
Z
by Barkworth
AMMJ Target 5.00 (Very high net profit margins+growth) #MJ Quarterly Semi-Annual Annual (Values in 000s | USD) Period Ending Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Total Revenue 990 952 617 339 Cost of Revenue 163 133 146 106 Gross Profit 826 819 470 233 Operating Expenses Research and Development 63 0 0 0 Sales, General and Admin. 435 478 679 413 Non-Recurring Items - - - - Other - - - - Operating Income 317 329 (214) (189) Income From Continuing Operations Add'l Income/Expense Items - - 8 (40) Earnings Before Interest and Tax 317 329 (214) (189) Interest Expense - - 0 - Earnings Before Tax 317 329 (206) (235) Income Tax - 0 0 - Minority Interest - - - - Equity Earnings Unconsolidated Subsidiary - - - - Net Income Cont. Operations 317 329 (206) (235) Non Recurring Events Discontinued Operations - - - - Extraordinary Items - - - - Effect of Accounting Changes - - - - Other Items - - - - Net Income 317 329 (206) (235) Preferred Stock and Other Adjustments - - - - Net Income Applicable to Common Shareholders 317 329 (206) (235) Assets Current Assets Cash and Cash Equivalents 1,877 1,675 1,663 751 Short Term Investments - - - - Net Receivables 404 193 117 164 Inventory 30 25 28 42 Other Current Assets 14 17 19 9 Total Current Assets 2,326 1,912 1,828 967 Long Term Investments - - - - Property Plant and Equipment 12 8 10 11 Goodwill - - - - Intangible Assets - - - - Accumulated Amortization - - - - Other Assets 4 4 59 4 Deferred Long Term Asset Charges - - - - Total Assets 2,344 1,925 1,898 983 Liabilities Current Liabilities Accounts Payable 34 130 228 92 Short Term and Current Long Term Debt - - - 0 Other Current Liabilities 57 12 434 222 Total Current Liabilities 92 142 663 329 Long Term Debt - - - - Other Liabilities - - - - Deferred Long Term Liability Charges - - - - Minority Interest - - - - Negative Goodwill - - - - Total Liabilities 92 142 663 329 Stockholders' Equity Misc. Stock Options Warrants - - - - Redeemable Preferred Stock - - - - Preferred Stock 0 0 - 0 Common Stock 0 0 0 0 Retained Earnings (4,235) (4,611) (4,940) (4,734) Treasury Stock - - - - Capital Surplus 6,486 6,393 6,176 5,389 Other Stockholder Equity - - - - Total Stockholder Equity 2,251 1,783 1,235 654 Net Tangible Assets 2,251 1,783 1,235 654
OTC:AMMJLong
by StockPicksNYC98